The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer.
OBJECTIVE
The clinical significance of preoperative serum levels of tumor markers CEA and CA19-9 was evaluated in gastric cancer patients.


METHODS
Serum levels of CEA and CA19-9 were measured in 663 patients with gastric cancer who underwent laparotomies over a recent 4-yr period (1990-1993). The correlations between the serum levels of tumor markers and several clinicopathological factors were evaluated by univariate analysis. The significance of the tumor markers as prognostic factors was assessed by multivariate analysis.


RESULTS
The positivity rates of CEA and CA19-9 were 16.6% and 16.0%, respectively. The positivity of CEA correlated well with the sex of the patients, hepatic, peritoneal, and nodal metastases and the depths of tumors, but it correlated weakly with a tumor's histological type. The positivity of CA19-9 correlated well with various forms of metastases, depths, and tumor size. A significant in prognosis was observed between patients positive and negative for CA19-9 among those undergoing R0 resection. Multivariate analysis also revealed that serum CA19-9 was better than CEA as a prognostic factor.


CONCLUSIONS
CA19-9 in the preoperative sera is a good prognostic factor in gastric cancer patients, although tumor markers continue to have only limited diagnostic usefulness.
Kodera
Y
Y
Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan.
Yamamura
Y
Y
Torii
A
A
Uesaka
K
K
Hirai
T
T
Yasui
K
K
Morimoto
T
T
Kato
T
T
Kito
T
T
D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay / Q000706:statistics & numerical data; D008297:Male; D011379:Prognosis; D016016:Proportional Hazards Models; D018709:Statistics, Nonparametric; D013274:Stomach Neoplasms / Q000276:immunology* / Q000401:mortality / Q000601:surgery; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen